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Abstract:
Few studies have examined the extent to which structural and
functional MRI, alone and in combination with genetic biomarkers, can predict
future cognitive decline in asymptomatic elders. This prospective study
evaluated individual and combined contributions of demographic information,
genetic risk, hippocampal volume, and fMRI activation for predicting cognitive
decline after an 18-month retest interval. Standardized neuropsychological
testing, an fMRI scans semantic memory task (famous name discrimination),
and structural MRI (sMRI) were performed on 78 healthy elders (73% female;
mean age = 73 years, range = 65 to 88 years). Positive family history of
dementia and presence of one or both apolipoprotein E (APOE) ε4 alleles
occurred in 51.3% and 33.3% of the sample, respectively. Hippocampal
volumes were traced from sMRI scans. At follow-up, all participants
underwent a repeat neuropsychological examination. At 18 months, 27
participants (34.6%) declined by at least 1 SD on one of three
neuropsychological measures. Using logistic regression, demographic
variables (age, years of education, gender) and family history of dementia did
not predict future cognitive decline. Greater fMRI activity, absence of an APOE
ε4 allele, and larger hippocampal volume were associated with reduced
likelihood of cognitive decline. The most effective combination of predictors
involved fMRI brain activity and APOE ε4 status. Brain activity measured from
task- activated fMRI, in combination with APOE ε4 status, was successful in
identifying cognitively intact individuals at greatest risk for developing
cognitive decline over a relatively brief time period. These results have
implications for enriching prevention clinical trials designed to slow AD
progression.
Keywords: aging, apolipoprotein E, cognitive decline, fMRI, hippocampal
volume, neuroimaging, memory.

INTRODUCTION
Alzheimer’s disease (AD) neuropathology begins decades before
the onset of observable symptoms [1]. Initiating interventions after
symptom onset may be too late to make a meaningful impact on
disease course. Clinical trials designed to prevent or slow AD
progression have dramatically intensified the search for valid
preclinical biomarkers. Extant biomarker studies have demonstrated
success in predicting conversion from mild cognitive impairment (MCI)
to AD using neuropsychological testing [2-5]; structural magnetic
resonance imaging (sMRI) measurement of hippocampal volume [6-8]
and rate of atrophy [9-11]; sMRI of entorhinal cortex volume [11-14];
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cerebrospinal fluid (CSF) indices including elevated isoprostane [1517], elevated total tau and phosphorylated tau [18-20], and low
amyloid-β (Aβ)42 levels [15, 21-23]; positron emission tomography
(PET) involving regional glucose metabolism [24, 25] and amyloid
imaging using the 11C Pittsburgh Compound B [26-28]; and taskactivated functional magnetic resonance imaging (fMRI); [29, 30]. A
more challenging task for prevention trials, however, is to identify
biomarkers capable of identifying asymptomatic older persons at-risk
for developing cognitive decline within the time frame required of a
prevention trial (2-3 years).
The apolipoprotein E (APOE) ε4 allele is a well-known risk factor
for late onset AD [31, 32], and healthy APOE ε4 carriers have
demonstrated faster cognitive decline than non-carriers [33-35].
However, the biomarker potential for APOE alone is limited, given that
the APOE ε4 allele frequency is less than 40% among AD cases [36,
37], and it has a low positive predictive value for AD diagnosis [3840]. Using test-retest intervals of approximately three years, studies
using fluorodeoxyglucose (FDG) PET [34] and CSF tau181/Aβ42 and
ptau181/Aβ42 ratios [41] have shown promise for predicting cognitive
decline in otherwise healthy older adults. The relative invasiveness of
these latter two approaches may preclude their routine use in
screening large numbers of cognitively intact participants for inclusion
in prevention trials.
Less invasive magnetic resonance imaging (MRI) techniques
provide more practical alternatives for identifying cognitively intact
older adults at risk for future cognitive decline. sMRI studies have
demonstrated that smaller hippocampal and entorhinal cortex volumes
at baseline predict cognitive decline in healthy elders [42-47]. A taskactivated fMRI study [48] has also shown that increased number and
spatial extent of activated regions at baseline can predict memory
decline after a two-year retest interval. Genetic risk in middle aged
women (family history of AD and at least one APOE ε4 allele) has been
associated with decreased fMRI activation in extrastriate and posterior
inferotemporal cortex at baseline, together with further decreases
after four years in these regions as well as left inferior frontal and
premotor cortex [49]. However, this decreased fMRI signal was not
associated with cognitive decline in this study. In contrast, using a
word categorization task during fMRI with APOE ε4 carriers, nine older
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adults showing cognitive stability on episodic memory testing after five
years demonstrated increased left inferior parietal activation at
baseline relative to nine participants who demonstrated episodic
memory decline; greater blood oxygen level dependent (BOLD) fMRI
response in this region was associated with better memory
performance after five years [50]. However, no hippocampal volume
differences were observed at baseline between stable and declining
participants. No study to date has directly compared the relative
sensitivity of sMRI and fMRI approaches, particularly over a relatively
brief interval (e.g., 1-2 years).
In this study, we compared the ability of sMRI and fMRI to
predict cognitive decline over 18 months in a sample of cognitively
intact older adults with varying degrees of AD risk, based on family
history of dementia and APOE ε4 allele carrier status. The sMRI
technique involved measurement of hippocampal volumes. The fMRI
task required the discrimination of famous from unfamiliar names. Our
previous studies using this task reported activation of a semantic
memory system, including bilateral hippocampi, posterior cingulate,
middle frontal gyrus, and lateral temporoparietal junction [51-53]. The
task can be performed with a high degree of accuracy (>90% correct)
even in symptomatic amnestic MCI patients [54]. In a cross-sectional
study [55], we demonstrated that the brain activation patterns of
healthy elders at risk for developing AD (APOE ε4, family history)
could be differentiated using this task. The current longitudinal
prospective study used logistic regression to compare the relative
efficacy of sMRI and fMRI, alone and in combination, for predicting
cognitive decline after an 18-month retest interval. Because a greater
potential exists for accelerated cognitive decline among APOE ε4
carriers [33-35], we examined APOE genotype as an additional
predictor of decline.

MATERIALS AND METHODS
Participants
Participants were 78 healthy older adults (73% female; Mage=73
years, SD= 4.9 years; Meducation=14.9 years, SD = 2.7 years). The
participants were drawn from a larger sample of 459 communitydwelling adults who were recruited via newspaper advertisements.
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Following telephone screening, 92 participants met study inclusion and
exclusion criteria, and 81 persons agreed to undergo ApoE genotyping
from blood samples, a neuropsychological evaluation, and an fMRI
scanning session. MRI data were not able to be obtained for three
participants. Family history was defined as a report of a clear clinical
diagnosis of AD or a reported history of gradual decline in memory and
other cognitive functions, confusion, or judgment problems without a
formal diagnosis of AD prior to death in a first-degree relative. One
participant reported a diagnosis of AD in a second degree relative, with
some mild cognitive changes noted in a parent prior to the parent’s
death. Because our study examined the influence of AD risk factors on
prediction of cognitive decline, half of the participants were purposely
selected because they had a positive family history of AD. We
expected that enrichment of our sample with persons with a positive
family history of AD would also increase the number of persons who
were APOE ε4 positive, because APOE ε4 tends to be more common
among individuals with a positive AD family history than among those
with a negative AD family history [56, 57].
Family history of dementia was present in 51.3% of
participants, and 33.3% of the sample carried the APOE ε4 allele. All
participants underwent neuropsychological evaluation (see below) and
were cognitively intact when entering the study. Informed consent was
obtained consistent with the Declaration of Helsinki and institutional
guidelines established by the Medical College of Wisconsin Human
Subjects Review Committee; all participants received financial
compensation.

Neuropsychological assessment and APOE genotyping
All participants underwent baseline neuropsychological testing,
fMRI scanning, and APOE genotyping. The neuropsychological battery
included the Mini-Mental State Examination [58], Mattis Dementia
Rating Scale-2 (DRS-2) [59, 60], Rey Auditory Verbal Learning Test
(RAVLT) [61], Geriatric Depression Scale [62], and Lawton
Instrumental Activities of Daily Living Scale (ADL) [63]. Alternate
forms of the DRS-2 [64, 65] and RAVLT [66] were used. APOE
genotype was determined using a PCR method [67]. DNA was isolated
with Gentra Systems Autopure LS for Large Sample Nucleic Acid
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Purification. All participants underwent a follow-up neuropsychological
examination after approximately 18 months.

Definition of cognitive decline
We defined cognitive decline as a reduction from baseline
performance of at least one SD on at least one of the three principal
outcome indices (DRS-2, RAVLT Sum of Trials 1-5 [T1-5], RAVLT
Delayed Recall [DR]). Residualized change scores were computed for
each cognitive measure by predicting T2 scores using T1 scores; this
procedure adjusts for baseline performance, practice effects, and
regression to the mean [68-70]. Participants with standardized
residuals of -1.0 or lower were assigned to the cognitively declining
group; the remaining participants were classified as cognitively stable.

fMRI task
For the fame discrimination task [53], stimuli consisted of 30
famous and 30 unfamiliar names randomly interspersed with 20
presentations of a centrally placed crosshair in order to introduce
“jitter” into the fMRI time series (interstimulus interval = 4 sec).
Participants made a right index or right middle finger key press for
famous or unfamiliar names, respectively. Accuracy and reaction time
were recorded, and nonparametric signal detection indices were
calculated [71]. The imaging run began and ended with 12 sec of
fixation and was 5 min and 44 sec in duration.

Image acquisition
Whole-brain, event-related fMRI was conducted on a General
Electric (Waukesha, WI) Signa Excite 3.0 Tesla short bore scanner
equipped with a quad split quadrature transmit/receive head coil.
Echoplanar images were collected using an echoplanar pulse sequence
(TE=25 ms; flip angle=77 degrees; field of view (FOV)=24 cm; matrix
size=64 x 64; TR=2s). Thirty-six contiguous axial 4-mm-thick slices
provided coverage of the entire brain (voxel size = 3.75 x 3.75 x 4
mm). High-resolution, three-dimensional spoiled gradient-recalled at
steady-state (SPGR) anatomic images were acquired (TE = 3.9 ms; TR
= 9.5 ms; inversion recovery (IR) preparation time = 450 ms; flip
angle = 12 degrees; number of excitations (NEX) = 2; slice thickness
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= 1.0 mm; FOV = 24 cm; resolution = 256 x 224). Foam padding was
used to reduce head movement within the coil.

Image analysis
Functional images were generated with the Analysis of
Functional NeuroImages (AFNI) software package [72]. Each image
series was time shifted to the beginning of the TR and spatially
registered to reduce head motion effects using a rigid body iterative
linear least squares method. A deconvolution analysis was used to
extract separate hemodynamic response functions (HRFs) for correctly
recognized famous and unfamiliar names. HRFs were modeled for the
0-16 second period post-stimulus onset. Motion parameters and
incorrect trials were incorporated into the model as nuisance
regressors. Area under the curve (AUC) was calculated by summing
the hemodynamic responses at time points 4, 6, and 8 seconds post
trial onset, a measure of the curve peak yielding maximum signal-tonoise. Anatomical and functional scans were transformed into standard
stereotaxic space [73]. To compensate for anatomical variation,
functional images were blurred using a 6 mm Gaussian full-width halfmaximum filter.

Spatial extent of activation for cognitively stable and
declining groups
Voxelwise t-tests were used to generate separate statistical
parametric maps for the stable and declining groups. These maps
indicate regions where the AUCs for famous and unfamiliar names
were significantly different. The statistical threshold was based on an
individual voxel probability (p = 0.005) coupled with a minimum
cluster volume (0.73 ml). These values were derived from 3,000
Monte Carlo simulations [74] and correspond to a whole brain familywise error threshold of p < 0.05.

Functional ROI analysis
A separate voxelwise t-test, comparing famous and unfamiliar
names, was conducted on all 78 participants using the identical
statistical threshold. This method identified significant cluster volumes,
which we refer to as functional regions of interest (fROIs). For each
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participant, an “average AUC” was calculated for all voxels within each
fROI. These data were then subjected to a principal components
analysis (PCA) to further reduce the number of regions that would
serve as predictors in the logistic regression analysis (see below).

Hippocampal volume measurement
Left and right hippocampal volumes were created using
Freesurfer [75, 76] and manually edited on T1-weighted SPGR images
by two raters blinded to participant group membership. Using coronal
views, the mask was further refined by excluding the fimbria and
alveus and retaining the hippocampus (uncal apex, cornu ammonis,
subiculum, gyrus of retzius, and fasciola cinerea). Hippocampal
volumes were normalized by dividing by the total intracranial volume.
Intraclass correlation for the two raters was 0.87. The left and right
hippocampal volumes were then summed to create a single score.

Data analysis
Statistical analyses were performed using R, version 2.9.0.
Group differences on demographics, total hippocampal volume, and
neuropsychological and fMRI task performance were compared using ttests and r2 effect size measures or Fisher’s Exact tests, as
appropriate. Logistic regression tested the ability of specific baseline
variables to discriminate between stable and declining participants. To
avoid overfitting the data and to maintain a reasonable subjects-tovariables ratio for each model, we restricted the set of predictors to no
more than four variables. Our models tested the effects of age,
education, and gender (Model 1); APOE ε4 status and dementia family
history (Model 2); hippocampal volume (Model 3); fMRI activation
(Model 4). Models 5 and 6 examined the additive effect of APOE ε4
status with either hippocampal volume or fMRI activation, respectively.
Model 7 combined APOE ε4 status with both imaging predictors. The
ability of these models to differentiate between stable and declining
participants was assessed using the Nagelkerke R2 and the
concordance or C index (related to the area under the receiver
operating characteristic curve [77]. The Nagelkerke R2 assesses the
importance of the predictors in a given model relative to a “perfectly
fitting” null model [78]. The C index reflects the proportion of all
possible pairs of declining and stable subjects in which the declining
Journal of Alzheimer’s Disease, Vol. 21, No. 3 (September 2010): pg. 871-885. DOI. This article is © IOS Press and
permission has been granted for this version to appear in e-Publications@Marquette. IOS Press does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from IOS
Press.

9

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

participant in the pair had a higher predicted probability of decline
than the stable participant [77]. Values of R2 and C for each logistic
regression model were validated with a bootstrapping analysis using
5000 resamples in order to assess each model’s accuracy of prediction
of decline across the entire range of probabilities [77]. This approach
yielded bootstrap-corrected values for R2 and C. Bootstrapping is the
most efficient model validation procedure, as it does not require
holding out any data for cross-validation, and each phase of model
development (including assessment of the degree of overfitting the
data) is revalidated using repeated resampling from the entire sample
[77].

RESULTS
Identification of cognitive decline
A total of 27/78 (34.6%) participants showed a one SD decline
on at least one of the three neuropsychological indices (DRS-2, RAVLT
Trials 1-5, and RAVLT Delayed Recall). These participants constituted
the cognitively declining group and the remaining participants formed
the stable group. Figure 1 illustrates performance changes on the
neuropsychological outcome measures for the stable and declining
groups. As expected, the stable group showed no significant
neuropsychological change after 18 months, while the declining group
demonstrated significant reductions on each of the three
neuropsychological indices.
Subjective memory complaints were present in 33.3% of the
declining group. Of the declining participants, 2 (7.6%) satisfied
criteria for MCI [79]. No participant demonstrated impaired ADL skills
at follow-up. Declining participants did not differ from stable
participants on age, education, gender, or neuropsychological retest
interval (Table 1). However, the APOE ε4 allele was over twice as
prevalent (51.9% versus 23.6%) among declining (3 ε2/ε3, 10 ε3/ε3,
14 ε3/ε4) than stable (5 ε2/ε3, 34 ε3/ε3, 11 ε3/ε4, 1 ε4/ε4)
participants.

Journal of Alzheimer’s Disease, Vol. 21, No. 3 (September 2010): pg. 871-885. DOI. This article is © IOS Press and
permission has been granted for this version to appear in e-Publications@Marquette. IOS Press does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from IOS
Press.

10

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Baseline neuropsychological testing and fMRI task
performance
On baseline measures (Table 1), no significant differences were
observed on the MMSE, DRS-2, RAVLT Trials 1-5, and RAVLT Delayed
Recall between the stable and declining groups after controlling for
multiple comparisons (Bonferroni adjusted alpha level = 0.0125;
0.05/4 tests). The stable group reported significantly more depressive
symptoms on the GDS, but no participant in either group was in the
clinically depressed range. None of the participants reported ADL
impairments at baseline.
On the fMRI fame discrimination task, no differences were
observed in accuracy, RT, or on a signal detection measure of
discriminability (d’) between the stable and declining groups. For
both groups, mean accuracy exceeded 90% for identification of
famous names and rejection of unfamiliar names.

Baseline sMRI
Declining participants had a significantly smaller total
hippocampal volume at baseline than cognitively stable participants
(Table 1).

Baseline fMRI
Figure 2 presents significant clusters based on a voxelwise
analysis performed separately for the stable and declining groups. The
spatial extent of activated voxels is greater in the stable than declining
group, with most of the differences reflecting more activation during
recognition of famous names relative to unfamiliar names. The
declining group showed a smaller amount of activated tissue, with
some regions showing the opposite pattern.
Figure 3A represents the results of the voxelwise analysis
performed on the entire sample. This analysis, restricted to the famous
> unfamiliar name comparison, yielded eight fROIs (Table 2). A PCA
was conducted on the average AUCs of these fROIs, yielding two
components accounting for 73% of total variance (Table 2). Five fROIs
loaded significantly on a “Cortical” component, shown in green in
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Figure 3A, whereas two regions loaded on the “Hippocampal”
component (purple regions in Figure 3A). The right cerebellum did not
demonstrate significant loadings [80] on either component and was
dropped from the analysis. The unfamiliar > famous name comparison
resulted in four fROIs and a single PCA component accounting for
63.3% of the total variance. This component did not predict cognitive
decline and is not discussed further.
Figure 3B presents a graph of the fMRI signal response to
famous and unfamiliar names compared to fixation (rather than just
the comparison of these conditions) to address the question of
whether the effect is driven primarily by activation to famous names or
the response to novel names. For cognitively stable participants, both
the Cortical and Hippocampal fMRI signal demonstrated positive
changes in the AUC in response to famous names and a decreased
AUC in response to unfamiliar names. In contrast, the cognitively
declining participants showed the opposite pattern, with greater AUC
in response to unfamiliar names and reduced AUC when presented
with unfamiliar names. Using a mixed-design ANOVA that tested the
effects of group (stable vs. declining) and stimulus type (famous vs.
unfamiliar), significant group by stimulus type interactions were
observed for the Cortical (F(1,76)=8.88, p<0.004) and Hippocampal
(F(1,76)=8.11, p=0.006) fMRI components.

Logistic regression analyses
Seven logistic regression models were evaluated. For each
model, bootstrap-corrected R2 and C values are presented in Table 3.
For each predictor within a model, coefficients, standard errors, and
significance levels are shown in Table 3, and odds ratios with 95%
confidence intervals are presented in Figure 4. Models 1 and 2 indicate
that age, education, gender and family history of AD were not
significant predictors of future cognitive decline. For Models 2-7, APOE
status, cortical and hippocampal fMRI activation, and hippocampal
volume each contributed significantly to the prediction of cognitive
decline. Although Model 7 demonstrates the largest R2 (0.293) and C
index (0.789), only two of the four predictors were statistically
significant (cortical fMRI activation and APOE status), whereas the
remaining two predictors (hippocampal fMRI and hippocampal volume)
were not. Model 5 (R2 = 0.285; C = 0.787) was the second best
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model, with APOE genotype and both cortical and hippocampal fMRI
activation each contributing significantly to the prediction of future
cognitive decline.
The Adequacy Index [77] is a recommended way of comparing
the adequacy of a set of predictors across models. It is unitless and is
represented by ratio of the -2 log likelihood statistic for testing a
subset of predictors for the model of interest to the -2 log likelihood
ratio statistic for testing the joint significance of the full set of
predictors. It ranges between 0 (no predictive information for the
subset of predictors) to 1 (complete predictive information for the
subset of predictors). Using the full set of predictors in Model 7, the
Adequacy Indexes for Models 2-6 are presented in Table 3. Model 1
was not included as there was no significant predictor of decline using
demographic variables. The fMRI measures alone (Model 3) account
for 46% of the total explanatory power for the set of variables,
compared to hippocampal volume alone (Model 4), which accounts for
only 27% of the total explanatory power. Perhaps more dramatically,
Model 5, which uses the fMRI measures plus APOE genotype status
accounts for 87% of the explanatory power compared to Model 6
(hippocampal volume plus APOE genotype status), which accounts for
only 43% of the explanatory power.

DISCUSSION
Clinical trials involving pharmacological and lifestyle (exercise,
cognitive enrichment, diet) interventions are being considered to
prevent or delay the onset of AD, even before symptoms emerge. For
clinical trials to be maximally successful, enrichment of the sample
with elders at the greatest risk for experiencing cognitive decline over
the course of a typical clinical trial (2-3 years) is essential. Results of
our prospective study indicate that combining genetic risk and MRI
biomarkers can effectively identify such individuals, even after a
relatively brief 18-month retest interval. Specifically, we were able to
correctly order 78.9% of possible pairs of stable and declining
participants using a combination of APOE genotype, cortical and
hippocampal fMRI, and hippocampal volumes. APOE genotype and
fMRI (cortical and hippocampal) predictors alone correctly ordered
78.7% of possible pairs. In contrast, hippocampal volume, alone or
combined with APOE status, correctly ordered only 68.7% and 70.2%
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of pairs, respectively. Without the benefit of imaging data, family
history of dementia and APOE status correctly ordered only 61.5% of
possible pairs (chance prediction = 50%). Overall, our findings suggest
that the combination of fMRI and APOE genotype status holds promise
for successfully screening at-risk, but asymptomatic, participants for
prevention trials.
Our results would appear to be at odds with a similar
prospective fMRI study [48], in which increased brain activation was
associated with lower scores on episodic memory tasks after a two
year retest interval. It is important to note two important
methodological differences between the two studies. First, the number
of participants who underwent follow-up neuropsychological testing in
the earlier study (n = 14) was considerably smaller than those in the
current study (n = 78). Second, the previous study used an effortful
episodic learning and recall task and did not report task performance
during fMRI scanning. It is conceivable that declining participants
performed more poorly at baseline on the fMRI task than those who
were stable over the retest interval. Such differences in task
performance, if present, could have a meaningful impact on the
pattern of brain activation, especially since error trials could not be
eliminated from the blocked design trial format used in the previous
fMRI study. In contrast, the current event-related study used a low
effort, high accuracy (>90% correct) semantic memory task in which
the few error trials that did occur were excluded from the final image
analyses.
In a previous study [55], we reported greater semantic memory
activation in cognitively intact, APOE ε4 carriers relative to noncarriers. As in the current study, we defined semantic memory
activation by a greater BOLD response to famous than unfamiliar name
stimuli. Based solely on the cross-sectional results reported in our
previous study, one might predict that greater semantic activation
would be a predictor of future cognitive decline. However, in our prior
study, we did not segregate declining from stable participants within
each of the two risk groups. The current longitudinal results suggest
that having increased semantic memory activation may paradoxically
afford a protective effect against future cognitive decline in both high
and low risk individuals. This effect is illustrated in Figure 5. The 12
APOE ε4 carriers in the stable group demonstrated greater cortical
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activation in response to familiar than unfamiliar names; in contrast,
the 14 declining APOE ε4 carriers exhibited greater activation to
unfamiliar than to familiar names. Among the non-carriers, a similar
pattern was observed, albeit with less overall semantic memory
activation for the group as a whole. Among the 39 stable non-carriers,
the degree of cortical activation was comparable for famous and
unfamiliar names, whereas the 13 declining non-carriers demonstrated
greater activation for unfamiliar than famous names.
Our finding that increased baseline fMRI activation is protective
against future cognitive decline in cognitively intact elders is consistent
with prior studies reporting increased task- related BOLD signal in
parietal cortex in cognitively stable participants after five years [50,
81]. Increased activation may reflect greater cognitive reserve in
asymptomatic persons, particularly in regions subserved by the
cholinergic system. Increased brain activation in these regions has
been observed following administration of cholinesterase inhibitors in
MCI and AD patients [82- 87]. We speculate that improved cognitive
reserve, possibly manifested by increased neuronal firing rate or
recruitment of additional supportive neuronal regions, permits
continued functioning at a higher level in the face of early
neurodegenerative changes. Persons who have lost this propensity for
functional compensation are at increased risk of future cognitive
deterioration.
Our famous name recognition task activates brain regions
(posterior cingulate gyrus, posterior inferior parietal cortex, middle
temporal gyrus, fusiform and parahippocampal gyri, hippocampus, and
medial superior frontal gyrus) commonly associated with the “default
mode network” (DMN) [88, 89]. The DMN is frequently correlated with
uncontrolled semantic processing resulting from task-unrelated
thoughts that occur during resting scan conditions. Prior work by
Binder and colleagues [90, 91] has demonstrated considerable overlap
between brain systems associated with the resting state DMN and
those activated by controlled semantic memory processing tasks.
Recent studies [92-94] have suggested that disruption of the DMN can
occur in early AD. Not surprisingly, our results have shown that
participants who have experienced cognitive decline after 18 months
also demonstrate reduced baseline semantic memory activation in
cortical regions that overlap with the DMN (see Figure 5). Moreover,
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the AUCs corresponding to the fMRI signal in both cortical and
hippocampal regions were reduced in response to famous names and
increased in response to unfamiliar names for cognitively declining
participants (Figure 3B). Cognitively stable participants showed the
opposite pattern. Future studies are required to determine the relative
sensitivity of baseline measurements of the resting state DMN versus
task-activated semantic memory processes in predicting future
cognitive decline among asymptomatic persons.
Baseline hippocampal volume, corrected for intracranial volume,
significantly predicted future cognitive decline, both alone and
combined with APOE genotype. However, its predictive accuracy was
not as strong as the combination of fMRI and APOE genotype.
Considerable inter- individual variability in hippocampal volumes
occurs in cross-sectional studies of cognitively intact elders, and
hippocampal volume may sometimes be inversely related to cognitive
abilities [95]. A recent meta-analysis concluded that the relationship
between hippocampal size and episodic memory performance across
the lifespan was weak [96]. While rate of hippocampal atrophy has
provided more compelling evidence of a relationship with cognitive
decline in healthy older adults [97-99], the requirement of two
measurement periods separated by up to two or more years makes
this biomarker impractical for widespread use for enriching prevention
trials.
This study adds to the growing body of literature showing that
combinations of biomarkers show greater predictive accuracy
compared to individual biomarkers [16, 100]. A stepwise combination
of biomarkers might be considered for balancing invasiveness, costcontainment, and predictive accuracy when used in the context of
identifying at-risk, but otherwise healthy, participants for prevention
trials. For instance, a prevention trial screening process might include
APOE genotyping as a first step, followed by task-related fMRI
activation performed in APOE ε4 carriers. More invasive tests, such as
CSF biomarkers and PET imaging (FDG or amyloid), could then be
administered as further selection criteria for enriching study samples.
However, because we did not perform these additional tests, we
cannot state conclusively whether these procedures provide
incremental predictive accuracy beyond the combination of APOE
genotyping and task-activated fMRI.
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It is important to acknowledge other limitations of this study.
Our neuropsychological battery focused on cognitive abilities most
likely to be affected in early AD and may have missed significant
changes in other cognitive domains among our stable participants. Our
study also defined cognitive decline based on change in
neuropsychological test scores rather than on a change in diagnostic
category, i.e., conversion to MCI or early AD. In our opinion, the rate
of conversion from intact cognition to MCI/AD is too low to be used as
a meaningful outcome variable in prevention trials. Nevertheless, the
extent to which increased baseline fMRI activation is specific to
predicting early AD-related changes or more general age-related
cognitive decline will await long-term follow-up studies. Finally, despite
the fact that all participants performed within normal limits at baseline
on all cognitive measures, baseline neuropsychological performance
demonstrated non-significant trends for lower performance in the
declining group on the two RAVLT measures and on the MMSE. Thus, it
is conceivable that several participants in the declining group were
actively undergoing cognitive decline. However, our outcome measure
was based on the degree of cognitive decline from baseline
performance (1 SD or more) rather than absolute levels of
performance. Furthermore, our regression-based approach to defining
cognitive change controlled each participant’s follow-up level of
performance for his or her baseline level of performance. Small
baseline differences would be unlikely to account for the dramatic
cognitive change in the declining group relative to the stable group as
depicted in Figure 1.
In summary, our study provides evidence of the ability of taskrelated fMRI, in combination with APOE genotype, to predict future
cognitive change in healthy older adults. This combination of static
genetic propensity to develop AD and an fMRI approach that measures
brain activity during a low-effort, high accuracy task, can be valuable
for enriching a prevention trial with healthy persons at high risk of
impending cognitive decline. Biomarker combinations tapping different
aspects of pathological changes associated with AD that are widely
available, easily implemented, minimally invasive, and relatively
inexpensive will likely assume increasing importance in future clinical
trials designed to prevent or slow AD progression.
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Table 1.

Sample characteristics, neuropsychological performance and fMRI

behavioral data for stable and declining groups.

Note:

MMSE=Mini-Mental State Examination; DRS-2=Mattis Dementia Rating Scale-

2; RAVLT=Rey Auditory Verbal Learning Test; DR = delayed recall; IADL=Instrumental
Activities of Daily Living; GDS=Geriatric Depression Scale; d’=signal detection
discrimination; RT=Reaction Time.
* = data were constant.

Table 2.

Activation foci for famous versus unfamiliar name subtraction (Famous >

Unfamiliar)*

Note:

Critical value (2*rcrit, p=.01) used to identify significant component loadings

was 0.560 [80]. *= PCA conducted on four negative activation (Unfamiliar > Familiar)
clusters (Left Precentral Gyrus; Bilateral Supplementary Motor Area; Right Insula; Left
Middle Occipital Gyrus) revealed one component that did not predict decline; this
component was dropped from subsequent analyses.
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Table 3.

Results of logistic regressions

Note: Adequacy index reflects the total explanatory power of a subset of
predictors relative to a model containing the total set of predictors (Model 7)
using the ratio of the likelihood ratio of the model of interest to the likelihood
ratio of the model containing the total set of predictors.

FIGURE LEGENDS
Figure 1. Mean baseline and follow-up performance (with standard
errors) on principal neuropsychological outcome measures for cognitively
stable and declining participants. There were no significant (p < 0.05) group
differences at baseline. The 18-month follow-up shows expected group
differences in cognitive functioning, validating the group selection criteria.

Figure 2. Group differences in activation derived from the
comparison of the famous versus unfamiliar names condition: Famous >
Unfamiliar represented in red; Unfamiliar > Famous in blue. Note the greater
spatial extent of activation in the Famous > Unfamiliar names comparison in
the stable group.

Figure 3. A) Regions comprising the Cortical (green) and
Hippocampal (purple) fMRI activation principal components for the Famous >
Unfamiliar names comparison. B) Cortical and Hippocampal fMRI signals
(areas under the curve) contrasting famous name recognition versus fixation
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and unfamiliar name identification versus fixation for cognitively stable and
declining participants.

Figure 4. Odds ratios and 95% confidence intervals for seven logistic
regression models. Odds ratios whose 95% confidence intervals overlap with
1.0 (represented by vertical dashed line) are not statistically significant. Odds
ratios > 1 indicate greater probability of decline with increasing value of
predictor; odds ratios < 1 indicate reduced probability with increasing
predictor values.
Figure 5. Percent MR signal intensity (± SEM) for stable and
declining APOE ε4 carriers (ε4+) and non-carriers (ε4-). Positive values reflect
greater BOLD response aggregated across activated cortical regions in
response to famous relative to unfamiliar names; negative values reflect
greater BOLD response to unfamiliar relative to familiar names.
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Figure 5
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